Skip to main content

enVVeno Medical Corp

NVNO
Exchange
Nasdaq
Industry
Surgical & Medical Instruments & Apparatus
SEC CIK
0001661053

In the last 90 days, enVVeno Medical Corp insiders filed 0 open-market purchases and 1 sale; 17 institutions reported holding it in 13F filings for Q2 2026, worth $953.6K in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by enVVeno Medical Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $123.31 in total
Insiders trading
1
Net value
−$123.31
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for enVVeno Medical Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for enVVeno Medical Corp
NameTitleLast reported holdingLast filingFilings, past year
Duhay FrancisDirector2,351Sep 14, 20265
Berman Robert AndrewChief Executive Officer222,236Dec 18, 20251
Glickman Marc H.SVP & Chief Medical Officer101,600Dec 18, 20251
Alavi HamedChief Technology Officer0Dec 18, 20251
Jenusaitis MatthewDirector16,545Dec 15, 20251
Shrivastava SanjayDirector9,288Dec 15, 20251
Gray RobertDirector11,155Dec 15, 20251
Bright JenniferChief Financial Officer–May 20, 20250
Glynn CraigChief Financial Officer50,000Dec 7, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 14, 2026 (view filing)6:56 PM ETSep 113 daysDuhay FrancisDirectorSSale−11$11.21−$123.31−0.5%2.35K after10b5-1
Jun 12, 2026 (view filing)Jun 111 dayDuhay FrancisDirectorSSale−140$10.31−$1.44K−5.6%2.36K after10b5-1
Mar 13, 2026 (view filing)Mar 121 dayDuhay FrancisDirectorSSale−140$11.52−$1.61K−5.3%2.50K after10b5-1
Dec 12, 2025 (view filing)4:40 PM ETDec 111 dayDuhay FrancisDirectorSSale−4.90K$0.3556−$1.74K−5.0%92.5K after10b5-1
Sep 17, 2025 (view filing)Sep 152 daysDuhay FrancisDirectorSSale−4.90K$0.83−$4.07K−4.8%97.4K after10b5-1
Jan 3, 2025 (view filing)Dec 31, 20243 daysDuhay FrancisDirectorPPurchase+81.4K$3.07+$250.0K+389.4%102.3K after
Jan 2, 2025 (view filing)Dec 31, 20242 daysGray RobertDirectorPPurchase+3.50K$2.94+$10.3K+45.7%11.2K after
Dec 26, 2024 (view filing)Dec 242 daysShrivastava SanjayDirectorPPurchase+5.40K$2.90+$15.7K+138.9%9.29K after
Dec 23, 2024 (view filing)Dec 194 daysJenusaitis MatthewDirectorPPurchase+9.62K$2.53+$24.3K+138.9%16.5K after
Dec 19, 2024 (view filing)Dec 19Same dayBerman Robert AndrewChief Executive OfficerPPurchase+12.0K$2.55+$30.6K+5.7%222.2K after
Mar 15, 2024 (view filing)Mar 132 daysAlavi HamedChief Technology OfficerSSale−8.33K$6.22−$51.8K−100.0%0 after
Aug 18, 2022 (view filing)Aug 162 daysDuhay FrancisDirectorPPurchase+7.75K$6.14+$47.6K+58.9%20.9K after
Jul 1, 2022 (view filing)Jun 301 dayShrivastava SanjayDirectorPPurchase+1.00K$3.85+$3.85K+34.6%3.89K after
Jun 28, 2022 (view filing)Jun 271 dayBerman Robert AndrewChief Executive OfficerPPurchase+2.50K$3.80+$9.50K+1.2%210.2K after
Nov 19, 2021 (view filing)Nov 19Same dayBerman Robert AndrewCEOPPurchase+2.00K$7.43+$14.9K+34.9%7.74K after
Nov 18, 2021 (view filing)Nov 162 daysBerman Robert AndrewCEOPPurchase+2.00K$7.87+$15.7K+53.5%5.74K after
Aug 27, 2021 (view filing)Aug 252 daysJenusaitis MatthewDirectorPPurchaseCommon Stock, $$0.00001 par value+1.30K$7.70+$10.0K+36.7%4.84K after